Envigo opens its doors for business

Published: 23-Sep-2015
Research & Development

The firm has been formed as a result of the integration of Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics and LSR


Huntingdon Life Sciences, Harlan Laboratories and three subsidiaries have re-branded as Envigo.

The firm, headquartered in Huntingdon, UK, employs 3,800 people and has sales approaching $500m. It provides non-clinical research services and research models and services to the pharmaceutical, chemical and crop protection industries, as well as academic institutions and government agencies worldwide.

Chief Executive Brian Cass said: 'Today we are delighted to officially re-brand as Envigo. This marks a significant milestone for the five companies that came together to create Envigo and demonstrates the great progress we have made in our integration.'

Adrian Hardy, COO, added: 'We have received very positive comments from customers to the on-going integration of our businesses and to our new name. Our goal is to establish the company as the number one partner for both customer service and scientific excellence.'

  • Companies:
  • Envigo
See more

You may also like

Manufacturing

(Cryo)preserving your research

Read more
Bringing welfare, logistical and cost benefits to modern preclinical drug development studies

Trending Articles

  1. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  2. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  5. Lonza aims to tackle bias concerns during blinded clinical trials Lonza has introduced an over-encapsulation product aimed at tackling concerns around bias during blinded clinical trials

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

(Cryo)preserving your research

Bringing welfare, logistical and cost benefits to modern preclinical drug development studies
Research & Development

In vivo models to target respiratory diseases

Envigo’s Steve Jordan offers intuitive analysis and insights into methods of optimising in vivo efficacy studies and predicts what developments might be coming to fruition in the future
Regulatory

Successful AAALAC accreditation for Envigo facilities in Barcelona, Spain

Envigo has announced that its contract research facilities in Barcelona, Spain have been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council
Research & Development

Envigo launches hepatotoxicity testing to drug development derisking programme

Envigo announces the launch of an integrated programme of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI) – one of the major causes of drugs being withdrawn from the market
Research & Development

Envigo invests in Science and Technology Advisory Group (STAG)

STAG will act as an internal funding body for promising research, develop new assays and technologies with customers
Research & Development

Huntingdon Life Sciences and Harlan announce new equity funding

The combined company, soon to be called Envigo, has received a commitment of up to US$125m in minority equity financing
Research & Development

Huntingdon Life Sciences and Harlan Laboratories to become Envigo

New company is created through the integration of the two companies which offer research models and services and contract research services
Subscribe now